Safety Study of Intranasal Etripamil for the Termination of Spontaneous Episodes of Paroxysmal Supraventricular Tachycardia (PSVT). NODE-302
A phase 3 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 169 participants.
Also called NCT03635996
- Study
- In this atlas
Overview
- Design
- Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 169 participants
- Registry
-
NCT03635996
-
- Other papers using this trial's data
- Etripamil Nasal Spray for Conversion of Repeated Spontaneous Episodes of Paroxysmal Supraventricular Tachycardia During Long-Term Follow-Up: Results From the NODE-302 Study
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Canada
- Registry status
- Terminated
Technical summary
Registry record NCT03635996. Allocation not applicable; no masking; primary purpose treatment. Start 2018-12-10 (actual); primary completion 2020-11-13 (actual). Results posted on 2023-04-24.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Safety Study of Intranasal Etripamil for the Termination of Spontaneous Episodes of Paroxysmal Supraventricular Tachycardia (PSVT). NODE-302
- Condition
- Paroxysmal Supraventricular Tachycardia
- Intervention (Drug)
- Etripamil NS 70 mg
- Intervention (Device)
- Aptar Pharma Nasal Spray Bidose System
- Lead sponsor
- Milestone Pharmaceuticals Inc.
- Collaborator
- Medpace, Inc.
Record details
- Record id
cardio:ct-nct03635996- Content hash
c92652334f1d0400a6ba4157e9b0814ca6b17fb5fd81deb6cc4ca29b16ecd05e